HomeCompareIMGN vs VICI

IMGN vs VICI: Dividend Comparison 2026

IMGN yields 6.40% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $958.3K in total portfolio value
10 years
IMGN
IMGN
● Live price
6.40%
Share price
$31.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$962.44
Full IMGN calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — IMGN vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMGNVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMGN + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMGN pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMGN
Annual income on $10K today (after 15% tax)
$544.26/yr
After 10yr DRIP, annual income (after tax)
$818.07/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $528,954.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMGN + VICI for your $10,000?

IMGN: 50%VICI: 50%
100% VICI50/50100% IMGN
Portfolio after 10yr
$509.7K
Annual income
$312,111.88/yr
Blended yield
61.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

IMGN
Analyst Ratings
6
Buy
15
Hold
1
Sell
Consensus: Hold
Price Target
$14.79
-52.6% upside vs current
Range: $6.36 — $22.00
Altman Z
18.1
Piotroski
3/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMGN buys
0
VICI buys
0
No recent congressional trades found for IMGN or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMGNVICI
Forward yield6.40%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$30.5K$988.8K
Annual income after 10y$962.44$623,261.32
Total dividends collected$8.1K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$14.79$31.60

Year-by-year: IMGN vs VICI ($10,000, DRIP)

YearIMGN PortfolioIMGN Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$11,340$640.31$11,368$948.43$28.00VICI
2$12,813$678.62$13,339$1,493.16$526.00VICI
3$14,426$716.58$16,326$2,426.21$1.9KVICI
4$16,190$754.03$21,123$4,112.15$4.9KVICI
5$18,114$790.87$29,379$7,368.23$11.3KVICI
6$20,209$826.97$44,804$14,191.64$24.6KVICI
7$22,486$862.25$76,658$29,972.12$54.2KVICI
8$24,957$896.64$150,894$71,015.81$125.9KVICI
9$27,634$930.05$350,814$193,582.47$323.2KVICI
10$30,531$962.44$988,809$623,261.32$958.3KVICI

IMGN vs VICI: Complete Analysis 2026

IMGNStock

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Full IMGN Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this IMGN vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMGN vs SCHDIMGN vs JEPIIMGN vs OIMGN vs KOIMGN vs MAINIMGN vs NNNIMGN vs EPRTIMGN vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.